Patient-derived Organoids of Lung Cancer to Test Drug Response
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Lung tumor resection.
- Who it may be relevant to
- Registry conditions: Lung Cancer, Organoid. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Switzerland
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This is a single center, single arm, open and exploratory clinical study, with 50 cases planned for a period of 3 years. The purpose of this study is to evaluate the consistency and accuracy of a Patient-Derived Organoid (PDO) Model of lung cancer to predict the clinical efficacy of anti-cancer drugs, in order to predict the best chemotherapy regimen for each given patient.
Detailed description
The aim of the project is to use a combination of patient-derived organoid models:
* To amplify tumour tissue to obtain enough material for genomic and histological analysis * to characterize the lung cancer sub-type * To predict treatment (non)response.
The following points will be addressed:
1. First, the investigators plan to establish and characterize formation of organoids from biopsies of patients with lung cancer: in spheroids, in the 3D cellular model OncoCilAirTM (OncoTheis), and on the chick chorioallantoic membrane (CAM). Patient-derived organoids from tumoural tissue (PDO) will be characterized and compared to the original tumour. 2. Second, the investigators will test the chemoresponse (chemosensitivity and chemoresistance) of organoids to anti-cancer treatment.
Interventions
- Procedure Lung tumor resection
lung tumor resection
Primary outcome measures
- Patient-derived organoid establishment [Time frame: 3 years]
- Patient-derived organoid validation [Time frame: 5 years]
Secondary outcome measures (2)
- Drug sensitivity [Time frame: 2019 - 2023]
- Prediction of the response to treatment by the patient-derived organoids [Time frame: 2020 - 2025]
Eligibility criteria
Inclusion criteria
- Histologically proven lung cancer
- Age ≥ 18
- Written informed and signed consent
- Accessible to biopsy and/or surgery sample of metastasis and/or primitive tumour
Exclusion criteria
- Less than 18 years of age
- Not able to give informed consent (language, intellectual capacities, etc.)
- Not accessible to biopsy and/or surgery sample
- Not enough lung tissue for a histological analysis or the remaining lung tissue is not enough to perform a routine pathological analysis.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Switzerland · 1 center
- Geneva University Hospitals — Geneva
Publications
- Mueggler A, Pilotto E, Perriraz-Mayer N, Jiang S, Addeo A, Bedat B, Karenovics W, Triponez F, Serre-Beinier V. An Optimized Method to Culture Human Primary Lung Tumor Cell Spheroids. Cancers (Basel). 2023 Nov 25;15(23):5576. doi: 10.3390/cancers15235576. PMID 38067281
Identifiers
NCT: NCT03979170 · 2018-02395